Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.36 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 2/20 | 0.33 |
| ▸ | TLR2 | O60603 | 1/20 | 0.33 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.33 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3232845 | 0.89 | ALDH1A1 (0.32) | ALDH1A1ENPP2 | |
| SCHEMBL5899432 | 0.80 | TSHR (0.36) | LMNABLMTDP1ALDH1A1TSHR | |
| SCHEMBL9893708 | 0.79 | TSHR (0.36) | ALDH1A1TSHRHTTGAANPSR1 | |
| SCHEMBL22684752 | 0.78 | ENPP2 (0.33) | TSHRENPP2ORAI1ORAI2ORAI3 | |
| SCHEMBL23554807 | 0.77 | LMNA (0.48) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL840950 | 0.77 | ENPP2 (0.32) | TDP1ALDH1A1SMN1; SMN2ENPP2ORAI1 | |
| SCHEMBL5952272 | 0.77 | ENPP2 (0.32) | ENPP2ORAI1ORAI2ORAI3 | |
| SCHEMBL3426496 | 0.77 | ALDH1A1 (0.38) | TDP1ALDH1A1TSHRCA2ENPP2 | |
| SCHEMBL4520012 | 0.77 | ENPP2 (0.32) | LMNATSHRENPP2ORAI1ORAI2 | |
| SCHEMBL15455586 | 0.76 | ALDH1A1 (0.39) | LMNABLMTDP1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9688906-B2 | Boronated biopolymer crosslinking agents and methods relating thereto | HALLIBURTON ENERGY SERVICS, INC. (US) | 2017-06-27 | — | — | US | claimed |
| US-20150075789-A1 | Boronated Biopolymer Crosslinking Agents and Methods Relating Thereto | HALLIBURTON ENERGY SERVICES, INC. (US) | 2015-03-19 | — | — | US | claimed |
| WO-2015002669-A1 | BORONATED BIOPOLYMER CROSSLINKING AGENTS AND METHODS RELATING THERETO | HALLIBURTON ENERGY SERVICES, INC. (US) | 2015-01-08 | — | — | WO | claimed |
| US-9688906-B2 | Boronated biopolymer crosslinking agents and methods relating thereto | HALLIBURTON ENERGY SERVICS, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| EP-2957558-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2015-12-23 | — | — | EP | disclosed |
| US-9024071-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20150075789-A1 | Boronated Biopolymer Crosslinking Agents and Methods Relating Thereto | HALLIBURTON ENERGY SERVICES, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| WO-2015002669-A1 | BORONATED BIOPOLYMER CROSSLINKING AGENTS AND METHODS RELATING THERETO | HALLIBURTON ENERGY SERVICES, INC. (US) | 2015-01-08 | — | — | WO | disclosed |
| EP-2757105-A1 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | Abbvie Inc. (US) | 2014-07-23 | — | — | EP | disclosed |
| EP-2550258-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbvie Inc. (US) | 2013-01-30 | — | — | EP | disclosed |
| US-8343967-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LABORATORIES (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120214796-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. | 2012-08-23 | — | — | US | disclosed |
| US-8236783-B2 | ROS-sensitive iron chelators and methods of using the same | DUKE UNIVERSITY (US) | 2012-08-07 | — | — | US | disclosed |
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8188077-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| WO-2011119345-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-09-29 | — | — | WO | disclosed |
| US-20110237553-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-09-29 | — | — | US | disclosed |
| US-20100004204-A1 | ROS-SENSITIVE IRON CHELATORS AND METHODS OF USING THE SAME | DUKE UNIVERSITY | 2010-01-07 | — | — | US | disclosed |
| WO-2008020920-A1 | ROS-SENSITIVE IRON CHELATORS AND METHODS OF USING THE SAME | DUKE UNIVERSITY (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | LMNA 3453/4885KMT2A 4328/4885MEN1 4590/4885 |
| US-20120214796-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | LMNA 2607/4885KMT2A 3558/4885MEN1 3502/4885 |
| US-20110237553-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | LMNA 2607/4885KMT2A 3558/4885MEN1 3502/4885 |
| US-20100004204-A1 | ROS-SENSITIVE IRON CHELATORS AND METHODS OF USING THE SAME | ROS1, NFE2L2, GPX1 | LMNA 3993/4885KMT2A 1893/4885MEN1 4508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.